Wednesday, September 23, 2026. 12 PM-1 PM ET Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on July 21, 2026 with Nick Fingland, PhD, PMP, Senior Director R&D Operations and Science, BD, and Chris Farnsworth, PhD D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
June 2026—CAP TODAY publisher Bob McGonnagle spoke on March 12 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Jesse M. Young, PhD, medical director for TriCore Research Institute’s research and clinical trials department and director of point-of-care testing. Dr. Young is also clinical assistant professor at the University of New Mexico.
Bob McGonnagle: Dr. Young, tell us about TriCore and the laboratories you oversee.
Dr. Young (TriCore): TriCore Reference Laboratory is a full-service diagnostic laboratory. The core laboratory offers about 2,900 test codes and has a modality similar to that of Labcorp and Quest, but we’re focused on New Mexican populations. We serve most of the hospitals in the area and have statewide collection sites whereby we’re trying to expand health care and provide coverage for our communities so everyone in the state has access to health care near their home instead of having to drive six hours to the nearest collection site, drive home, and then be called back for a critical value. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
April 2026—CAP TODAY publisher Bob McGonnagle spoke on Feb. 19 with Thermo Fisher Scientific’s Ravi Gupta, MBA, VP and general manager; Robert Balog, PhD, MBA, senior director, research and development; and Poulomi Acharya, PhD, senior director, global product management and market development, genetic sciences.
Bob McGonnagle: Thermo Fisher launched last fall the SwiftArrayStudio, a next-generation microarray analyzer that will support genomics research and clinical applications through the use of laboratory-validated and -developed tests. Ravi Gupta, what motivated the development of this analyzer?
Ravi Gupta: The SwiftArrayStudio resulted from listening to customers. It addresses the scientific and operational pressures observed in modern genomics. I call them the real-world needs. For decades, labs across human predictive genomics and agrigenomics have dealt with persistent challenges in workflow complexity, inconsistent turnaround times, and escalating costs. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Thermo Fisher Scientific.
February 2026—CAP TODAY publisher Bob McGonnagle spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup. McGonnagle’s questions and their answers follow. A few of the questions came from the roundtable audience and are identified as such.
Bob McGonnagle: Steve, how long have you been with ELITech and what is your background in molecular diagnostics?
Steve Swartzell: I am director of customer experience and have been with ELITechGroup for 22 years. My background is in microbiology. I started as a research scientist in R&D and I was an application specialist working directly with customers. I have many years of lab experience as well. Now I oversee all the field activities for ELITechGroup MDx in the U.S. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ELITechGroup.
November 2025—CAP TODAY publisher Bob McGonnagle spoke on Oct. 1, 2025 with Sarah Stewart of Telcor, which sells laboratory revenue cycle management software and services, and Jeanette Gray and Scott Rupnow of Pathology Associates of San Antonio and Pathology Reference Laboratory.
Bob McGonnagle: Jeanette Gray, tell us about your laboratory.
Jeanette Gray, vice president of revenue and payer relations, Pathology Associates of San Antonio and Pathology Reference Laboratory: We are a physician-owned practice in San Antonio and we operate a laboratory that does primarily anatomic pathology and women’s health testing. We have about 20-plus pathologists on staff. I joined the practice in July. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Telcor.
August 2025—CAP TODAY publisher Bob McGonnagle spoke on May 14 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Meghan Starolis, MS, PhD, HCLD(ABB), senior science director for infectious diseases at Quest Diagnostics, Chantilly, Va.
Bob McGonnagle: Jessica Van Allen, I’d like to talk about some of the hot topics in molecular infectious disease testing, and you mentioned in our discussions offline that viral load testing for transplant viruses is becoming ever more important in the field. Can you make a few remarks about that?
Jessica Van Allen, PhD (ZeptoMetrix): There’s testing that is done using laboratory-developed tests and testing performed using FDA-cleared assays. Those are the two big buckets of testing in the labs of our customers. Meghan and I attended a conference recently at which a couple of the speakers talked about viral load testing for common transplant viruses—EBV, CMV, VZV, some adenoviruses. We’ve been playing in that field for a long time in terms of molecular controls for viruses, so they’re products we’ve had on the shelf. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
April 2025—CAP TODAY publisher Bob McGonnagle spoke with Anthony Alburo, MBA, market development manager, diagnostics, Tosoh Bioscience, Melanie Samko, director of marketing, Tosoh Bioscience, and Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare. Anthony Alburo opens the conversation.
Anthony Alburo: Tosoh Bioscience has a longstanding legacy in immunoassay diagnostics and HPLC [high-performance liquid chromatography] technology. Our immunoassay platforms support comprehensive cancer care with reimbursable tests for oncology, endocrinology, reproductive health, and chronic disease management. Our HPLC column solution has set the standard in A1C testing, a key factor in managing diabetes, which can intersect with cancer treatment. We remain committed to advancing laboratory science to support clinicians and patients at every stage of care.
I’m honored to introduce Melanie Samko, our director of marketing, who brings not only a deep expertise in health care marketing but also a deep personal perspective: She is a breast cancer survivor. Her journey highlights the real-world impact of early detection, diagnostic accuracy, and patient advocacy. Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare, which recently merged with the US Oncology Network, has extensive expertise in laboratory operations and compliance. She will provide invaluable insights into the challenges and advancements in oncology diagnostics. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Tosoh Bioscience in recognition of National Cancer Prevention Month.
